This article is part of the Thematic Series \"Synthesis in the glycosciences II\".

Introduction
============

*Mycoplasmas* constitute a family of gram-positive microbes lacking rigid cell walls. They are suspected to be associated with human immune diseases, in either direct or indirect ways, although the molecular mechanism is not fully understood \[[@R1]\]. In recent biochemical studies, *Mycoplasma* outer-membrane lipoproteins \[[@R2]--[@R3]\] and glycolipids \[[@R4]--[@R6]\] are thought to serve not only as the main antigens but also as probable pathogens. Also in our research team, Matsuda et al. \[[@R7]--[@R10]\] isolated a new class of α-glycolipid antigens (GGPL-I and GGPL-III, [Fig. 1](#F1){ref-type="fig"}) from *M. fermentans*. Another α-glycolipid (MfGL-II), which has a chemical structure very close to GGPL-III, was identified and characterized by other groups \[[@R11]--[@R14]\]*.*

![Absolute chemical structures of *M. fermentans* α-glycolipid antigens, GGPL-I and GGPl-III (GGPL: Glycosyl-*sn*-glycerophospholipid).](Beilstein_J_Org_Chem-08-629-g002){#F1}

Absolute chemical structures of GGPL-I \[[@R15]\] and GGPL--III \[[@R16]\] have already been established by chemical syntheses of stereoisomers; these α-glycolipids have a common chemical backbone of 3-*O*-(α-D-glucopyranosyl)-*sn*-glycerol carrying phosphocholine at the sugar primary (6-OH) position. The fatty acids at the glycerol moiety are saturated, namely palmitic acid (C~16:0~) and stearic acid (C~18:0~). GGPL-I has a structural feature analogous to 1,2-di-*O*-palmitoyl phosphatidylcholine (DPPC) as a ubiquitous cell membrane phospholipid. Apparently, GGPLs are amphiphilic compounds that can form certain self-assembled structures under physiological conditions \[[@R12]--[@R13]\] and may give physicochemical stress on the immune system of the host \[[@R17]\]. In fact, our research team has proven that these α-glycolipid antigens have certain pathogenic functions \[[@R18]--[@R19]\].

In order to exploit their biological functions in detail, it is necessary to obtain these α-glycolipids in sufficient amounts. Thus, both genetic \[[@R20]--[@R22]\] and chemical synthetic approaches \[[@R23]--[@R24]\] are being followed, although no practical way has yet been established. In this paper, we report a chemical access to both a natural GGPL-I homologue (C~16:0~) and its diastereomer **I-a** and **I-b**, in which our one-pot α-glycosylation methodology \[[@R25]--[@R26]\] is effectively applied. The two GGPL-I isomers prepared thereby were characterized with ^1^H NMR spectroscopy, in terms of configuration and conformation at the asymmetric glycerol moiety.

Results and Discussion
======================

A practical synthetic access to GGPL-I homologues
-------------------------------------------------

GGPL-I provides two key asymmetric centers to be controlled, literally, in the synthetic pathway. One is the configuration at the chiral glycerol moiety, and another is the sugar α-glycoside linkage. In former synthetic works on 3-*O*-(α-D-glycopyranosyl)-*sn*-glycerol \[[@R27]--[@R30]\], chiral 1,2-*O*-isopropylidene-*sn*-glycerol has often been employed \[[@R29]--[@R30]\] as the acceptor substrate for different α-glycosylation reactions. In this case, however, attention should be paid to the acid-catalyzed migration of the dimethylketal group \[[@R23],[@R29]--[@R31]\]. In our synthetic pathway, chiral (*S*)- or (*R*)-glycidol is employed as an alternative source of the chiral glycerol to circumvent this problem. In an established synthetic approach, 6-*O*-acetyl-2,3,4-tri-*O*-benzyl protected sugar **1** \[[@R23]\] is used as the donor and treated with a reagent combination of CBr~4~ and Ph~3~P (Appel--Lee reagent) in either CH~2~Cl~2~ or DMF solvent, or a mixture of the two ([Scheme 1](#C1){ref-type="fig"}). For the reaction in CH~2~Cl~2~, *N*,*N*,*N'*,*N'*-tetramethylurea (TMU) is added after in situ formation of α-glycosyl bromide **2**, which equilibrates with a more reactive β-glycosyl bromide species \[[@R32]\]. In the pathway using DMF, the α-glycosylation is routed via α-glycosyl cationic imidate **3**, which was predicted in former studies \[[@R33]\] and evidenced in our preceding NMR and MS study \[[@R25]--[@R26]\].

![An established synthetic pathway to α-glycosyl-*sn*-glycerols **4a** and **5a**. A reagent combination of CBr~4~ and Ph~3~P (Appel--Lee reagent) is utilized in either CH~2~Cl~2~ or DMF as solvent.](Beilstein_J_Org_Chem-08-629-g007){#C1}

The reaction between **1** and (*S*)-glycidol in CH~2~Cl~2~ (+ TMU) gave a mixture of epoxy compound **4a** (60--70%) and bromide **5a** (30--40%). In **5a**, the oxirane ring was opened by nucleophilic Br^−^ ions produced by Ph~3~P and CBr~4~. Also in the DMF-promoted reaction, a mixture of **4a** (70--90%) and **5a** (10--30%) was derived. In both reaction pathways, however, the glycosylation was α-selective (α:β ≥ 90:10, yields \>80%) and not accompanied by isomerization at the glycerol moiety.

A mixture of **4a** and **5a** was used in the following chemical transformation ([Scheme 2](#C2){ref-type="fig"}). First, a *lyso*-glycolipid **6a** was derived after deprotection at the sugar hydroxymethyl position and S~N~2 substitution with cesium palmitate at the glycerol *sn-*1 position. Then, this compound was converted to glycolipid **8a** after sequential reaction of the temporary *tert*-butyldimethylsilyl (TBDMS) -protected sugar, and O-acylation at the glycerol 2-OH position to give **7a**, followed by removal of the TBDMS protecting group. For introducing the phosphocholine group at the sugar 6-OH position, we employed a phosphoroamidite method using 1*H*-tetrazole as a promoter \[[@R34]\]. First, **8a** was treated with 2-cyanoethyl-*N*,*N*,*N*',*N*'-tetraisopropyl phosphorodiamidite in the presence of 1*H*-tetrazole, and then with choline tosylate to give **9a**. After removal of the sugar *O*-benzyl group by catalytic hydrogenolysis, the GGPL-I homologue **I-a** was obtained. In the same way, the GGPL-I *sn*-isomer **I-b** was derived from a mixture of **4b** and **5b** available from the reaction between **1** and (*R*)-glycidol ([Scheme 1](#C1){ref-type="fig"} and [Scheme 2](#C2){ref-type="fig"}).

![Syntheses of GGPL-I homologue **I-a** and its isomer **I-b**. Conditions: (a) K~2~CO~3~, CH~3~OH; (b) cesium palmitate in DMF; (c) TBDMS chloride then palmitoyl chloride in pyridine + DMAP; (d) TFA in CH~3~OH; (e) (i) 2-cyanoethyl-*N*,*N*,*N*',*N*'-tetraisopropyl phosphorodiamidite, 1*H*-tetrazole and MS-4 Å in CH~2~Cl~2~; (ii) choline tosylate, 1*H*-tetrazole, (iii) *m*CPBA, (iv) aq. NH~3~ in CH~3~OH, (f) H~2~, Pd(OH)~2~/C in CH~3~OH.](Beilstein_J_Org_Chem-08-629-g008){#C2}

^1^H NMR characterization of **I-a**, **I-b** and the related glycerolipids
---------------------------------------------------------------------------

^1^H NMR spectroscopy provides a useful tool for discriminating between the two GGPL-I isomers as shown in [Fig. 2](#F2){ref-type="fig"}. A clear difference was observed in the chemical shifts of the glycerol methylene protons as designated by "a" and "b". Conversely, little difference was observed between the *sn*-isomers at the sugar H-1 signal as well as at the glycerol H-2 ([Table 1](#T1){ref-type="table"}). Natural GGPL-I and GGPL-III gave ^1^H NMR data very close to those of **I-a**, indicating that both have a common skeleton of 3-*O*-(α-D-glucopyranosyl)-*sn*-glycerol \[[@R15]--[@R16]\].

![^1^H NMR spectra of **I-a** and **I-b** (500 MHz, 25 °C, CDCl~3~/CD~3~OD 10:1). The assignment of *sn*-glycerol methylene protons (H*~proR~* and H*~proS~*) was performed on the basis of our preceding studies on deuterium-labeled glycerols \[[@R35]--[@R37]\] and α(1→6)-linked disaccharides \[[@R38]--[@R40]\].](Beilstein_J_Org_Chem-08-629-g003){#F2}

###### 

^1^H NMR data (500 MHz) of **I-a**, **I-b**, and their precursors (**9a** and **9b**).

  ---------------------------------------- ------------ ---------------------- ------------------ ------ ------------ ------------------
  δ \[ppm\] ( ^3^*J* and ^2^*J* \[Hz\] )                                                                              
                                                                                                                      
  Compound                                 glucose      *sn*-glycerol moiety                                          
                                                                                                                      
  H-1'                                     H-1          H-2                    H-3                                    
                                                                                                                      
  *proR*                                   *proS*       *proR*                 *proS*                                 
                                                                                                                      
  **I-a**^a^                               4.80 (3.5)   4.14 (6.5)             4.40 (3.5, 12.0)   5.24   3.76 (5.5)   3.61 (5.5, 11.0)
  **9a**                                   4.70 (3.5)   4.17 (6.5)             4.38 (3.0, 12.0)   5.22   3.72 (5.5)   3.52 (6.0, 11.0)
  **I-b**^a^                               4.80 (3.5)   3.80 (6.0)             3.57 (5.5,11.0)    5.23   4.34 (3.5)   4.20 (6.5,12.0)
  **9b**                                   4.74 (3.5)   3.76 (5.5)             3.57 (5.5, 11.0)   5.23   4.37 (3.0)   4.19 (6.5, 12.0)
  ---------------------------------------- ------------ ---------------------- ------------------ ------ ------------ ------------------

^a^These α-glycolipids were dissolved in a mixture of CDCl~3~ and CD~3~OD (10:1) at 11.2 mM concentration.

The glycerol moiety has two C--C single bonds. By free rotation, each of them is allowed to have three staggered conformers of *gg* (*gauche-gauche*), *gt* (*gauche-trans*) and *tg* (*trans-gauche*) ([Fig. 3](#F3){ref-type="fig"}). In solution and also in self-contacting liquid-crystalline states, these conformers are thought to equilibrate with each other. In this study, we calculated time-averaged populations of the three conformers by means of ^1^H NMR spectroscopy. As we reported in a preceding paper \[[@R41]\], the Karplus-type equation proposed by Haasnoot et al.\[[@R42]\] was adapted as follows:

2.8*gg* + 3.1*gt* + 10.7*tg* = ^3^ *J* ~H2,H1S~ (or ^3^ *J* ~H2,H3R~)

0.9*gg* + 10.7*gt* + 5.0*tg* = ^3^ *J* ~H2,H1R~ (or ^3^ *J* ~H2,H3S~) and

*gg* + *gt* + *tg* = 1.

In this equation, a perfect staggering (Φ1 and Φ2 = +60, −60 or 180 degree) is assumed for every conformer. [Fig. 3](#F3){ref-type="fig"} summarizes the results for a series of 3-substituted 1,2-di-*O*-palmitoyl-*sn*-glycerols, which involve tripalmitin ([Fig. 3](#F3){ref-type="fig"}, entry 1), DPPC (1,2-di-*O*-palmitoylphosphatidylcholine) ([Fig. 3](#F3){ref-type="fig"}, entry 2), and GGPL-I homologues ([Fig. 3](#F3){ref-type="fig"}, entries 3--5). In a solution state with a mixture of CDCl~3~ and CD~3~OD (10:1) as the solvent and at a concentration of 11.2 mM, tripalmitin adopts the three conformers in the ratio of *gt* (45%), *gg* (37%) and *tg* (18%). In comparison with this symmetric lipid, the asymmetric phospholipid (DPPC) favors the *gt*-conformer more strongly around the tail lipid moiety along the *sn*-1,2 position, while disfavoring the *tg*-conformer, in the ratio of *gt* (59%), *gg* (34%) and *tg* (7%). The head phosphate moiety along the *sn*-2,3 position adopts the three conformers in equilibrated populations (*gg* = *gt* = *tg*).

![Distributions of *gg*, *gt* and *tg-*conformers in 3-substituted *sn*-glycerols at 11 mM in solutions of CDCl~3~ and CD~3~OD (10:1) at 298 K.](Beilstein_J_Org_Chem-08-629-g004){#F3}

3-*O*-(α-D-glucopyranosyl)-*sn*-glycerolipids **10** and **11** ([Fig. 3](#F3){ref-type="fig"}, entries 3 and 4) were found to have conformational properties very similar to DPPC; the lipid tail moiety prefers the *gauche* conformations (*gt* and *gg*), while the sugar moiety allows a random conformation. Here, it should be mentioned that the conformer distribution coincides between **I-a** ([Fig. 3](#F3){ref-type="fig"}, entry 5) and DPPC ([Fig. 3](#F3){ref-type="fig"}, entry 2) at the head moiety \[*gt* (33%), *gg* (34%) and *tg* (33%)\].

The above analysis was carried out also for the stereoisomer **I-b** and the related glycolipids ([Fig. 4](#F4){ref-type="fig"}, entries 6--8). The isomer ([Fig. 4](#F4){ref-type="fig"}, entry 8) showed an overall conformational property similar to **I-a** and DPPC ([Fig. 5](#F5){ref-type="fig"}), although a small difference was observed in the conformer distribution at the sugar head moiety. However, it should be recognized here that the helical direction (helicity) of the *gt* conformer in **I-b** is reversed (anticlockwise) from the case of DPPC and GGPL-I (clockwise), as depicted in [Fig. 3](#F3){ref-type="fig"} and [Fig. 4](#F4){ref-type="fig"}.

![Distributions of *gg*, *gt* and *tg-*conformers in 1-substituted *sn*-glycerols. In these *sn*-isomers, Φ1 and Φ2 represent the dihedral angles around the C--C single bond at the glycerol *sn*-2,3 and 1,2-position, respectively.](Beilstein_J_Org_Chem-08-629-g005){#F4}

![A common conformational property of GGPL-I and DPPC. The tail lipid moiety favors two *gauche*-conformers of *gt* and *gg* (*gt \> gg \>\> tg*), while the head moiety takes three conformers in averaged populations (*gt* = *gg* = *tg*).](Beilstein_J_Org_Chem-08-629-g006){#F5}

Conclusion
==========

We have proposed a synthetic pathway to a GGPL-I homologue and its stereoisomer, in which our one-pot α-glycosylation methodology was effectively applied. We envisage that the simple method will allow us to prepare a variety of α-glycolipid antigens other than GGPLs and to prove their biological significance \[[@R43]\]. By the ^1^H NMR conformational analysis, which was based on our former studies on deuterium-labeled *sn*-glycerols and sugars, we have proven that GGPL-I and other 3-*O*-(α-D-glucopyranosyl)-*sn*-glycerolipids have a common conformational property at the chiral glycerol moiety: The lipid tail moiety prefers two *gauche*-conformations (*gg* and *gt*) in the order *gt* \> *gg \>\> tg,* while the sugar head moiety adopts three conformers in an averaged population (*gg* = *gt* = *tg*). At the lipid tail position, the *gt-*conformer with clockwise helicity is predominant over the anticlockwise *gg*-conformer. The observed conformation was very close to what we have seen in DPPC ([Fig. 5](#F5){ref-type="fig"}). Although these results were based on the solution state in a solvent mixture of CHCl~3~ and CH~3~OH (10:1), it may be possible to assume that the mycoplasma GGPLs and the related 3-*O*-(α-D-glycopyranosyl)-*sn*-glycerolipids can constitute cytoplasm membranes in good cooperation with ubiquitous phospholipids without inducing stereochemical stress at the membrane.

The GGPL-I isomer **I-b** showed an overall conformational property similar to the natural isomer **I-a** and DPPC. However, it should be mentioned here that the chiral helicity of *gt*-conformers in **I-b** is reversed (anticlockwise) from the clockwise helicity of DPPC and GGPL-I. The difference in chirality seems critical in biological recognition events and also in physicochemical contact with other chiral constituents in cell membranes \[[@R44]--[@R45]\].

Experimental
============

General methods
---------------

Infrared (IR) spectra were recorded on a JASCO FT/IR-230 Fourier transform infrared spectrometer on KBr disks. All ^1^H NMR (500 MHz) spectra were recorded by using a Varian INOVA-500 or Varian Gemini 200. ^1^H chemical shifts are expressed in parts per million (δ ppm) by using an internal standard of tetramethylsilane (TMS = 0.000 ppm). Mass spectra were recorded with a JEOL JMS 700 spectrometer for fast atom bombardment (FAB) spectra. Silica gel column chromatography was performed on silica gel 60 (Merck 0.063--0.200 mm and 0.040--0.063 mm) and eluted with a mixture of toluene and ethyl acetate or a mixture of CHCl~3~ and CH~3~OH in gradient modes (100:0 to 80:20). For purification of phosphocholine-containing products, a chromatographic column packed with Iatrobeads (IATRON LABORATORIES INC., 6RS-8060) was applied and eluted with a mixture of CH~3~OH and CHCl~3~ in gradient modes. For thin-layer chromatography (TLC) analysis, Merck precoated TLC plates (silica gel 60 F~254~, layer thickness 0.25 mm) and Merck TLC aluminum roles (silica gel 60 F~254~, layer thickness 0.2 mm) were used. All other chemicals were purchased from Tokyo Kasei Kogyo Co., Ltd., Kishida Chemical Co., Ltd., and Sigma--Aldrich Chemical Company Co, Int., and were used without further purification.

**A typical procedure for the one-pot α-glycosylation:** CBr~4~ (1.6 g, 6.09 mmol) and Ph~3~P (2.02 g, 6.09 mmol) were added to a solution of 6-*O*-acetyl-2,3,4-tri-*O*-benzyl-D-glucose (**1**) (1.0 g, 2.03 mmol) in 10 mL of DMF and stirred for 3 h at rt. Then, (*S*)-glycidol (301 mg, 4.06 mmol) was added to the reaction mixture and stirred for 14 h at rt. Products were diluted with a mixture of toluene and ethyl acetate (10:1), and the solution was washed with saturated aq. NaHCO~3~ and aq. NaCl solution, dried and concentrated. The residue was purified by silica gel column chromatography in toluene and ethyl acetate to give a mixture of **4a** and **5a** (the ratio changed with reaction time) as colorless syrup. The total yield of **4a** and **5a** was between 80% and 90%.

**3-** ***O*** **-(2,3,4-tri-** ***O*** **-benzyl-α-D-glucopyranosyl)-1,2-di-** ***O*** **-palmitoyl-** ***sn*** **-glycerols 8a and 8b**: K~2~CO~3~ (379 mg, 2.74 mmol) was added to the mixture of **4a** and **5a** (1 g, 1.83 mmol based on **4a**) in CH~3~OH (20 mL) and stirred for 1 h at rt. The reaction mixture was neutralized, washed with water, dried, and concentrated. The residue was dried under reduced pressure and directly subjected to the next reaction. A mixture of caesium palmitate (2.7 g, 7.3 mmol) in DMF (40 mL) was heated at 100--110 °C, to which the DMF solution of the above residue was added slowly. The reaction mixture was stirred for 2 h at 110 °C, cooled to rt, and then filtered through a pad of Celite powder with ethyl acetate. The filtrate was washed with saturated aq. NaCl solution, dried, and concentrated. The residue was purified by silica gel column chromatography to give **6a** as a colorless syrup (830 mg, 60% yield). To a solution of **6a** (300 mg, 0.39 mmol) in pyridine (20 mL), TBDMS chloride (107 mg, 0.71 mmol) and 4-*N,N*-dimethylaminopyridine (cat.) were added. The reaction mixture was stirred for 12 h at rt, treated with methanol (2 mL) for 3 h and concentrated. The residue was purified by silica gel column chromatography in a mixture of toluene and ethyl acetate. The main product was dissolved in pyridine (20 mL) and then reacted with palmitoyl chloride (162 mg, 0.59 mmol) for 3 h at rt. The reaction mixture was treated with methanol (2 mL) and then concentrated with toluene. The residue was dissolved in a mixture of CH~3~OH and CH~2~Cl~2~ (1:1, 20 mL) and treated with trifluoroacetic acid (1 mL) for 2 h at rt. After concentration, the residue was purified by silica gel column chromatography in a mixture of toluene and ethyl acetate to give **8a** as a white waxy solid (0.32 g, 81% yield from **6a**). \[α\]~D~ ^30^ +21.1 (*c* 1.0, CHCl~3~); IR (KBr, film): 3413, 2923, 2853, 1736, 1630, 1457, 1361, 1158, 1069, 736 cm^−1^; ^1^H NMR (500 MHz, CDCl~3~): δ~H~ 7.40--7.23 (m, 5H × 3, -CH~2~C~6~ *H* ~5~), 5.23 (m, 1H, glycerol H-2), 4.96--4.64 (d, 2H × 3,-C*H* *~2~*C~6~H~5~), 4.70 (d, 1H, *J* = 3.5 Hz, H-1), 4.40 (dd, 1H, *J* = 4.0 and 12.0 Hz, glycerol H-1~proS~), 4.19 (dd, 1H, *J* = 6.0 and 12.0 Hz, glycerol H-1~proR~), 3.96 (dd, 1H, *J* = 9.5 and 9.5 Hz, H-3), 3.72 (dd, 1H, *J* = 5.5 and 10.5 Hz, glycerol H-3~proR~), 3.72 and 3.66 (b, 2H, H-6~ProR~ and H-6~proS~), 3.65 (m, 1H, H-5), 3.54 (dd, 1H, *J* = 5.5 and 10.5 Hz, glycerol H-3~proS~), 3.50 (dd, 1H, *J* = 9.5 and 10.0 Hz, H-4), 3.49 (dd, 1H, *J* = 3.5 and 9.5 Hz, H-2), 2.29 (m, 2H × 2, -OCOC*H* *~2~*CH~2~(CH~2~)~12~CH~3~), 1.58 (b, 2H × 2, -OCOCH~2~C*H* *~2~*(CH~2~)~12~CH~3~), 1.25 (b, 24H × 2, -OCOCH~2~CH~2~(C*H* *~2~*)~12~CH~3~), 0.88 (t, 3H × 2, *J* = 7.0 Hz, -OCOCH~2~CH~2~(CH~2~)~12~C*H* *~3~*); FABMS *m*/*z*: \[M + Na\]^+^ 1023.7.

In the same way as derived for the synthesis of **8a**, (*R*)-glycidol and **6b** (0.30 g, 0.39 mmol) was used for the synthesis of **8b** (0.30 g, 77% yield). \[α\]~D~ ^32^ +18.5 (*c* 1.0, CHCl~3~); IR (KBr, film): 3452, 2924, 2854, 1739, 1586, 1455, 1296, 1159, 1095, 710 cm^−1^; ^1^H NMR (500 MHz, CDCl~3~): δ~H~ 7.40--7.23 (m, 5H × 3, -CH~2~C~6~ *H* *~5~*), 5.23 (b, 1H, glycerol H-2), 4.96--4.63 (d, 2H × 3,-CH~2~C~6~H~5~), 4.75 (d, 1H, *J* = 3.5 Hz, H-1), 4.38 (dd, 1H, *J* = 3.5 and 12.0 Hz, glycerol H-3~proR~), 4.21 (dd, 1H, *J* = 6.5 and 12.0 Hz, glycerol H-3~proS~), 3.96 (dd, 1H, *J* = 9.5 and 9.5 Hz, H-3), 3.73 (dd, 1H, *J* = 6.0 and 11.0 Hz, glycerol H-1~proS~), 3.76 and 3.66 (b, 2H, H-6~ProR~ and H-6~proS~), 3.65 (m, 1H, H-5), 3.57 (dd, 1H, *J* = 5.5 and 11.0 Hz, glycerol H-1~proR~), 3.51 (dd, 1H, *J* = 9.5 and 10.0 Hz, H-4), 3.50 (dd, 1H, *J* = 3.5 and 9.5 Hz, H-2), 2.29 (b, 2H × 2, -OCOC*H* *~2~*CH~2~(CH~2~)~12~CH~3~), 1.59 (b, 2H × 2, -OCOCH~2~C*H* *~2~*(CH~2~)~12~CH~3~), 1.25 (b, 24H × 2, -OCOCH~2~CH~2~(C*H* *~2~*)~12~CH~3~), 0.88 (t, 3H × 2, *J* = 7.0 Hz, -OCOCH~2~CH~2~(CH~2~)~12~C*H* *~3~*); FABMS *m*/*z*: \[M + Na\]^+^ 1023.7.

A phosphorodiamidite method for the synthesis of **I-a**
--------------------------------------------------------

\(a\) The reaction vessel was kept under anhydrous conditions with Ar gas in the presence of molecular sieves (50%w/w), and a solution of **8a** (0.20 g, 0.20 mmol) and 2-cyanoethyl-*N*,*N*,*N*\',*N*\'-tetraisopropyl phosphorodiamidite (90.4 mg, 0.30 mmol) in 10 mL of CH~2~Cl~2~ was injected. 1*H*-tetrazole (28.4 mg, 0.40 mmol) was added and stirred for 2 h at rt. Then 1*H*-tetrazole (42.6 mg, 0.60 mmol, 3.0 equiv) and choline tosylate (220.3 mg, 0.8 mmol: thoroughly dried overnight under vacuum) were added to the reaction mixture and stirred for 1.5 h at rt. The reaction was quenched by the addition of water (1 mL), and then *m*-chloroperbenzoic acid (51.8 mg, 0.3 mmol) was added at 0 °C and stirred for 10 min at rt. The reaction mixture was washed with 10 % aq. Na~2~SO~3~ solution, saturated aq. NaHCO~3~ solution, water and saturated aq. NaCl solution, dried and concentrated. The residue was dissolved in a mixture of CH~3~OH (10 mL) and 30% aq. NH~3~ (1 mL) and stirred for 15 min at rt. The reaction mixture was concentrated, and the residue was purified by column chromatography (IATROBEADS in a mixture of CHCl~3~ and CH~3~OH) to give **9a** (186 mg, 80% yield). \[α\]~D~ ^26^ +13.0 (*c* 0.45, CHCl~3~); IR (KBr, film): 3301, 2929, 2856, 2537, 1731, 1577, 1419, 1216, 1093, 925, 788, 746; ^1^H NMR (500 MHz, CDCl~3~): δ~H~ 7.35--7.25 (m, 5H × 3, -CH~2~C~6~ *H* *~5~*), 5.22 (m, 1H, glycerol H-2), 4.93--4.61 (d, 2H × 3, -CH~2~C~6~ *H* *~5~*), 4.70 (d, 1H, *J* = 3.5 Hz, H-1), 4.38 (dd, 1H, *J* = 3.0 and 12.0 Hz, glycerol H-1~proS~), 4.19 (b, 2H, choline -C*H* *~2~*CH~2~N^+^(CH~3~)~3~), 4.17 (dd, 1H, *J* = 6.5 and 12.0 Hz, glycerol H-1~proR~), 4.15 and 4.02 (m, 2H × 2, H-6~ProR~ and H-6~proS~), 3.93 (dd, 1H, *J* = 9.0 and 9.5 Hz, H-3), 3.72 (dd, 1H, *J* = 5.5 and 11.0 Hz, glycerol H-3~proR~), 3.71 (b, 1H, H-5), 3.62 (t, 1H, H-4), 3.58 (b, 2H, choline -CH~2~C*H* *~2~*N^+^(CH~3~)~3~), 3.52 (dd, 1H, *J* = 6.0 and 11.0 Hz, glycerol H-3~proS~), 3.46 (dd, 1H, *J* = 3.5 and 9.5 Hz, H-2), 3.15 (s, 9H, -POCH~2~CH~2~N^+^(C*H* *~3~*)~3~), 2.28 (m, 2H × 2, -OCOC*H* *~2~*CH~2~(CH~2~)~12~CH~3~), 1.58 (b, 2H × 2, -OCOCH~2~C*H* *~2~*(CH~2~)~12~CH~3~), 1.25 (b, 24H × 2, -OCOCH~2~CH~2~(C*H* *~2~*)~12~CH~3~), 0.88 (t, 3H × 2, *J* = 7.0 Hz, -OCOCH~2~CH~2~(CH~2~)~12~C*H* *~3~*); FABMS *m*/*z*: \[M + Na\]^+^ 1188.7.

\(b\) Compound **9a** (0.18 g, 0.15 mmol) was hydrogenated with Pd(OH)~2~/C (8 mg) under atmospheric pressure in a mixture of CH~3~OH (10 mL) and acetic acid (0.1 mL) for 7 h at rt. The reaction mixture was neutralized by the addition of Et~3~N, filtered and concentrated. The residue was purified by column chromatography with IATROBEADS (CH~3~OH and CHCl~3~) to give **I-a** (101 mg, 75% yield). \[α\]~D~ ^31^ +18.7 (*c* 1.0, CHCl~3~/CH~3~OH 10:1); IR (KBr, film): 3372, 2927, 2852, 1731, 1573, 1469, 1112, 975, 727; ^1^H NMR (500 MHz, CDCl~3~/CD~3~OD 10:1): δ~H~ 5.23 (m, 1H, glycerol H-2), 4.80 (d, 1H, *J* = 3.5 Hz, H-1), 4.39 (dd, 1H, *J* = 3.5 and 12.0 Hz, glycerol H-1~proS~), 4.30 (b, 2H, -C*H* *~2~*CH~2~N^+^(CH~3~)~3~), 4.24 and 3.95 (b, 2H, H-6~ProR~ and H-6~proS~), 4.14 (dd, 1H, *J* = 6.5 and 12.0 Hz, glycerol H-1~proR~), 3.75 (dd, 1H, *J* = 5.5 and 11.0 Hz, glycerol H-3~proR~), 3.67 (b, 2H, choline-CH~2~C*H* *~2~*N^+^(CH~3~)~3~), 3.65 (b, 1H × 2, H-3 and H-5), 3.61 (dd, 1H, *J* = 5.5 and 11.0 Hz, glycerol H-3~proS~), 3.56 (b, 1H, H-4), 3.46 (b, 1H, H-2), 3.22 (s, 9H, -POCH~2~CH~2~N^+^(C*H* *~3~*)~3~), 2.31 (m, 2H × 2, -OCOC*H* *~2~*CH~2~(CH~2~)~12~CH~3~), 1.60 (b, 2H × 2, -OCOCH~2~C*H* *~2~*(CH~2~)~12~CH~3~), 1.25 (b, 24H × 2, -OCOCH~2~CH~2~(C*H* *~2~*)~12~CH~3~), 0.88 (t, 3H × 2, *J* = 7.0 Hz, -OCOCH~2~CH~2~(CH~2~)~12~C*H* *~3~*); HRMS--FAB (*m*/*z*): \[M + Na\]^+^ calcd for C~46~H~90~NO~13~PNa, 918.6048; found, 918.6028.

In the same way as described above, **9b** (180 mg) was derived from **8b** (200 mg, 0.20 mmol) in 76% yield and converted to the GGPL-I isomer **I-b** \[70 mg, 81% yield from **9b** (120 mg)\]. **9b:** \[α\]~D~ ^26^ +8.1 (*c* 0.62, CHCl~3~); IR (KBr, film): 3413, 2923, 2857, 1735, 1461, 1241, 1097, 744, 495, 445; ^1^H NMR (500 MHz, CDCl~3~): δ~H~ 7.35--7.23 (m, 5H × 3, -CH~2~C~6~ *H* ~5~), 5.23 (b, 1H, glycerol H-2), 4.94--4.64 (d, 2H × 3,-C*H* *~2~*C~6~H~5~), 4.74 (d, 1H, *J* = 3.5 Hz, H-1), 4.37 (dd, 1H, *J* = 3.0 and 12.0 Hz, glycerol H-3~proR~), 4.23 (b, 2H, choline-C*H* *~2~*CH~2~N^+^(CH~3~)~3~), 4.19 (dd, 1H, *J* = 6.5 and 12.0 Hz, glycerol H-3~proS~), 4.16 and 4.09 (b, 2H, H-6~proR~ and H-6~proS~), 3.94 (dd, 1H, *J* = 9.5 and 9.5 Hz, H-3), 3.76 (dd, 1H, *J* = 5.5 and 11.0 Hz, glycerol H-1~proS~), 3.72 (m, 1H, H-5), 3.61 (dd, 1H, *J* = 9.0 and 9.5 Hz, H-4), 3.60 (b, 2H, choline-CH~2~C*H* *~2~*N^+^(CH~3~)~3~), 3.57 (dd, 1H, *J* = 5.5 and 11.0 Hz, glycerol H-1~proR~), 3.49 (dd, 1H, *J* = 3.5 and 9.5 Hz, H-2), 3.20 (s, 9H, choline-CH~2~CH~2~N^+^(C*H* *~3~*)~3~), 2.28 (dd, 2H × 2, *J* = 7.5 and 15 Hz, -OCOC*H* *~2~*CH~2~(CH~2~)~12~CH~3~), 1.58 (b, 2H × 2, -OCOCH~2~C*H* *~2~*(CH~2~)~12~CH~3~), 1.25 (b, 24H × 2, -OCOCH~2~CH~2~(C*H* *~2~*)~12~CH~3~), 0.88 (t, 3H × 2, *J* = 7.0 Hz, -OCOCH~2~CH~2~(CH~2~)~12~C*H* *~3~*); FABMS *m*/*z*: \[M + Na\]^+^ 1188.7. **I-b:** \[α\]~D~ ^31^= +10.7 (*c* 1.0, CHCl~3~/CH~3~OH 10:1); IR (KBr film): 3390, 2919, 2856, 1731, 1463, 1228, 1074, 964, 711; ^1^H NMR (500 MHz, CDCl~3~/CD~3~OD 10:1): δ~H~ 5.24 (m, 1H, glycerol H-2), 4.80 (d, 1H, *J* = 3.5 Hz, H-1), 4.34 (dd, 1H, *J* = 3.5 and 12.0 Hz, glycerol H-3~proR~), 4.28 (b, 2H, choline-C*H* *~2~*CH~2~N^+^(CH~3~)~3~), 4.25 and 3.97 (b, 2H, H-6~ProR~ and H-6~proS~), 4.20 (dd, 1H, *J* = 7.0 and 12.0 Hz, glycerol H-3~proS~), 3.80 (dd, 1H, *J* = 6.0 and 11.0 Hz, glycerol H-1~proS~), 3.63 (b, 1H × 2, H-3 and H-5), 3.63 (b, 2H, choline-CH~2~C*H* *~2~*N^+^(CH~3~)~3~), 3.58 (dd, 1H, *J* = 5.5 and 11.0 Hz, glycerol H-1~proR~), 3.55 (b, 1H, H-4), 3.46 (dd, 1H, H-2), 3.22 (s, 9H, choline-CH~2~CH~2~N^+^(C*H* *~3~*)~3~), 2.31 (dd, 2H × 2, *J* = 7.5 and 15 Hz, -OCOC*H* *~2~*CH~2~(CH~2~)~12~CH~3~), 1.60 (b, 2H × 2, -OCOCH~2~C*H* *~2~*(CH~2~)~12~CH~3~), 1.26 (b, 24H × 2, -OCOCH~2~CH~2~(C*H* *~2~*)~12~CH~3~), 0.88 (t, 3H × 2, *J* = 7.0 Hz, -OCOCH~2~CH~2~(CH~2~)~12~C*H* *~3~*); HRMS--FAB (*m*/*z*): M + Na\]^+^ calcd for C~46~H~90~NO~13~PNa, 918.6048; found, 918.6078.

**3-** ***O*** **-(α-D-glucopyranosyl)-1,2-di-** ***O*** **-palmitoyl-** ***sn*** **-glycerol (10, entry 3)**: Compound **10** was obtained as a waxy solid (73 mg, 83% yield) from **8a** (120 mg, 0.12 mmol) by catalytic hydrogenation under the same reaction conditions as those described above for the preparation of **I-a**. \[α\]~D~ ^30^ +27.2 (*c* 1.0, CHCl~3~/CH~3~OH 10:1); IR (KBr, film): 3411, 2919, 2851, 1739, 1587, 1465, 1158, 1053, 720 cm^−1^; ^1^H NMR (500 MHz, CDCl~3~/CD~3~OD 10:1): δ~H~ 5.25 (m, 1H, glycerol H-2), 4.83 (d, 1H, *J* = 3.5 Hz, H-1), 4.40 (dd, 1H, *J* = 3.5 and 12.0 Hz, glycerol H-1~proS~), 4.16 (dd, 1H, *J* = 6.5 and 12.0 Hz, glycerol H-1~proR~), 3.82 (dd, 1H, *J* = 5.5 and 10.5 Hz, glycerol H-3~proR~), 3.78 (d, 2H, *J* = 3.5 Hz, H-6~proR~ and H-6~proS~), 3.65 (t, 1H, *J* = 9.5 and 9.5 Hz, H-3), 3.62 (dd, 1H, *J* = 6.0 and 10.5 Hz, glycerol H-3~proS~), 3.56 (dt, 1H, H-5), 3.44 (dd, 1H, *J* = 3.5 and 9.5 Hz, H-2), 3.42 (dd, 1H, *J* = 8.5 and 10.0 Hz, H-4), 2.32 (dt, 2H × 2, -OCOC*H* *~2~*CH~2~(CH~2~)~12~CH~3~), 1.61 (b, 2H × 2, -OCOCH~2~C*H* *~2~*(CH~2~)~12~CH~3~), 1.26 (b, 24H × 2, -OCOCH~2~CH~2~(C*H* *~2~*)~12~CH~3~), 0.88 (t, 3H × 2, *J* = 7.0 Hz, -OCOCH~2~CH~2~(CH~2~)~12~C*H* *~3~*); HRMS--FAB (*m*/*z*): \[M + Na\]^+^calcd for C~41~H~78~O~10~Na, 753.5493;found, 753.5519.

**3-** ***O*** **-(6-** ***O*** **-palmitoyl-α-D-glucopyranosyl)-1,2-di-** ***O*** **-palmitoyl-** ***sn*** **-glycerol (11, entry 4):** A mixture of **8a** (120 mg, 0.12 mmol) and palmitoyl chloride (165 mg, 0.6 mmol) in pyridine was stirred at rt for 3 h and then treated with CH~3~OH (1 mL) for 3 h. After concentration in vacuo, the residue was purified on silica gel (toluene/ethyl acetate). The main product (138 mg) was dissolved in a mixture of cyclohexene/ethanol 1:4 and subjected to catalytic hydrogenation at atmospheric pressure in the presence of Pd(OH)~2~/C (50 mg). The product was purified by silica gel column chromatography (CH~3~OH/CHCl~3~) to afford **11** (99 mg, 85% yield from **8a**). \[α\]~D~ ^30^ +20.9 (*c* 1.0, CHCl~3~/CH~3~OH 10:1); IR (KBr, film): 3414, 2919, 2851, 1739, 1605, 1465, 1375, 1176, 1054, 720 cm^−1^; ^1^H NMR (500 MHz, CDCl~3~/CD~3~OD 10:1): δ~H~ 5.25 (m, 1H, glycerol H-2), 4.82 (d, 1H, *J* = 4.0 Hz, H-1), 4.40 (dd, 1H, *J* = 3.5 and 12.0 Hz, glycerol H-1~proS~), 4.34 and 4.30 (dd × 2, 2H, *J* = 5.0 and 12.0, 2.5 and 12.0 Hz, H-6~proR~ and H-6~proS~), 4.16 (dd, 1H, *J* = 6.5 and 12.0 Hz, glycerol H-1~proR~), 3.82 (dd, 1H, *J* = 5.0 and 10.5 Hz, glycerol H-3~proR~), 3.73 (m, 1H, H-5), 3.65 (dd, 1H, *J* = 9.0 and 9.5 Hz, H-3), 3.61 (dd, 1H, *J* = 5.5 and 10.5 Hz, glycerol H-3~proS~), 3.45 (dd, 1H, *J* = 4.0 and 9.5 Hz, H-2), 3.33 (dd, 1H, *J* = 9.0 and 10.0 Hz, H-4), 2.33 (m, 2H × 3, -OCOC*H* *~2~*CH~2~(CH~2~)~12~CH~3~), 1.61 (b, 2H × 3, -OCOCH~2~C*H* *~2~*(CH~2~)~12~CH~3~), 1.26 (b, 24H × 3, -OCOCH~2~CH~2~(C*H* *~2~*)~12~CH~3~), 0.88 (t, 3H × 3, *J* = 7.0 Hz, -OCOCH~2~CH~2~(CH~2~)~12~C*H* *~3~*); HRMS--FAB (*m*/*z*): \[M + Na\]^+^ calcd for C~57~H~108~O~11~Na, 991.7789; found, 991.7832.
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